KR100360954B1 - 페닐알칸올아민유도체,이의제조방법및이를함유하는신경변성질환억제또는예방용약제 - Google Patents

페닐알칸올아민유도체,이의제조방법및이를함유하는신경변성질환억제또는예방용약제 Download PDF

Info

Publication number
KR100360954B1
KR100360954B1 KR1019940021962A KR19940021962A KR100360954B1 KR 100360954 B1 KR100360954 B1 KR 100360954B1 KR 1019940021962 A KR1019940021962 A KR 1019940021962A KR 19940021962 A KR19940021962 A KR 19940021962A KR 100360954 B1 KR100360954 B1 KR 100360954B1
Authority
KR
South Korea
Prior art keywords
formula
compound
methyl
phenylmethyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019940021962A
Other languages
English (en)
Korean (ko)
Other versions
KR950008481A (ko
Inventor
어노모학시
제이필립오브라이언
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR950008481A publication Critical patent/KR950008481A/ko
Application granted granted Critical
Publication of KR100360954B1 publication Critical patent/KR100360954B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Solid Fuels And Fuel-Associated Substances (AREA)
  • Table Devices Or Equipment (AREA)
  • Fats And Perfumes (AREA)
  • Organic Insulating Materials (AREA)
  • Indole Compounds (AREA)
KR1019940021962A 1993-09-02 1994-09-01 페닐알칸올아민유도체,이의제조방법및이를함유하는신경변성질환억제또는예방용약제 Expired - Fee Related KR100360954B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11638593A 1993-09-02 1993-09-02
US08/116.385 1993-09-02

Publications (2)

Publication Number Publication Date
KR950008481A KR950008481A (ko) 1995-04-17
KR100360954B1 true KR100360954B1 (ko) 2003-04-16

Family

ID=22366865

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940021962A Expired - Fee Related KR100360954B1 (ko) 1993-09-02 1994-09-01 페닐알칸올아민유도체,이의제조방법및이를함유하는신경변성질환억제또는예방용약제

Country Status (22)

Country Link
EP (1) EP0648744B1 (cg-RX-API-DMAC7.html)
JP (1) JP2610784B2 (cg-RX-API-DMAC7.html)
KR (1) KR100360954B1 (cg-RX-API-DMAC7.html)
CN (1) CN1061035C (cg-RX-API-DMAC7.html)
AT (1) ATE162520T1 (cg-RX-API-DMAC7.html)
AU (1) AU7149794A (cg-RX-API-DMAC7.html)
BR (1) BR9403418A (cg-RX-API-DMAC7.html)
CA (1) CA2129771C (cg-RX-API-DMAC7.html)
CZ (1) CZ210694A3 (cg-RX-API-DMAC7.html)
DE (1) DE69408078T2 (cg-RX-API-DMAC7.html)
DK (1) DK0648744T3 (cg-RX-API-DMAC7.html)
ES (1) ES2113585T3 (cg-RX-API-DMAC7.html)
FI (1) FI107607B (cg-RX-API-DMAC7.html)
GR (1) GR3026622T3 (cg-RX-API-DMAC7.html)
HU (1) HUT70558A (cg-RX-API-DMAC7.html)
IL (1) IL110812A0 (cg-RX-API-DMAC7.html)
NO (1) NO943231L (cg-RX-API-DMAC7.html)
NZ (1) NZ264320A (cg-RX-API-DMAC7.html)
PL (1) PL304863A1 (cg-RX-API-DMAC7.html)
RU (1) RU94031753A (cg-RX-API-DMAC7.html)
TW (1) TW281670B (cg-RX-API-DMAC7.html)
ZA (1) ZA946529B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658909A (en) * 1994-11-17 1997-08-19 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1'-yl propanones to treat Alzheimer's Disease
US6214994B1 (en) 1997-04-21 2001-04-10 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1′-yl propanones
US5693804A (en) * 1994-11-17 1997-12-02 Molecular Geriatrics Corporation Substituted 1-aryl-3-piperazin-1'-yl propanones
FR2742051B1 (fr) * 1995-12-06 1998-02-06 Synthelabo Utilisation de composes ayant une affinite pour le site de liaison du (3h)ifenprodil pour la fabrication de medicaments utiles dans la prevention et le traitement des neuropathies
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
BR9814867A (pt) 1997-10-24 2000-10-03 Warner Lambert Co Método para tratar discinesias relacionadas a doenças ou induzidas por drogas
GB9804885D0 (en) 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
DE19812331A1 (de) * 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
IL159393A (en) * 2001-07-24 2011-01-31 Richter Gedeon Vegyeszet Piperidine derivatives, pharmaceutical compositions containing them, processes for their preparation and uses thereof
JP4737418B2 (ja) 2003-09-25 2011-08-03 塩野義製薬株式会社 Ｎｍｄａ受容体拮抗作用を有するピペリジン誘導体
KR20140097132A (ko) 2011-11-22 2014-08-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 허혈성 손상을 치료하기 위한 시스테아민 및/또는 시스타민
RU2649406C1 (ru) * 2017-09-21 2018-04-03 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) 3-n-замещенные борнилпропионаты, используемые в качестве ингибиторов вируса марбург

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4261285A (en) * 1984-06-01 1985-12-05 Tokyo Tanabe Company Limited 1-propanone derivatives
DE3433036A1 (de) * 1984-09-08 1986-03-20 Basf Ag, 6700 Ludwigshafen Piperidinderivate und diese enthaltende fungizide sowie verfahren zur bekaempfung von pilzen
EP0398578B1 (en) * 1989-05-17 1997-03-12 Pfizer Inc. 2-piperidino-1-alkanol derivatives as antiischemic agents
US4940789A (en) * 1989-10-10 1990-07-10 American Home Products Corporation 10,11-dihydro-5-alkyl-12-substituted-10,5-(iminomethano)-5H-dibenzo[a,d]cycloheptenes as neuroprotectant agents
ATE154010T1 (de) * 1990-10-15 1997-06-15 Astra Ab 2-phenyl- und 2-thienyl-(2)-piperidinderivate mit neuroprotektiven eigenschaften
SE9003652D0 (sv) * 1990-11-15 1990-11-15 Astra Ab New heterocyclic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of medicinal chemistry *

Also Published As

Publication number Publication date
FI107607B (fi) 2001-09-14
HU9402479D0 (en) 1994-10-28
HUT70558A (en) 1995-10-30
ATE162520T1 (de) 1998-02-15
TW281670B (cg-RX-API-DMAC7.html) 1996-07-21
ZA946529B (en) 1995-03-02
CN1061035C (zh) 2001-01-24
ES2113585T3 (es) 1998-05-01
EP0648744B1 (en) 1998-01-21
KR950008481A (ko) 1995-04-17
NZ264320A (en) 1996-02-27
CN1105990A (zh) 1995-08-02
CA2129771A1 (en) 1995-03-03
EP0648744A1 (en) 1995-04-19
BR9403418A (pt) 1996-09-03
AU7149794A (en) 1995-03-16
NO943231D0 (no) 1994-09-01
PL304863A1 (en) 1995-03-06
DE69408078T2 (de) 1998-07-09
DE69408078D1 (de) 1998-02-26
NO943231L (no) 1995-03-03
FI944044L (fi) 1995-03-03
GR3026622T3 (en) 1998-07-31
JP2610784B2 (ja) 1997-05-14
IL110812A0 (en) 1994-11-11
DK0648744T3 (da) 1998-09-21
RU94031753A (ru) 1996-07-20
FI944044A0 (fi) 1994-09-02
CZ210694A3 (en) 1995-08-16
CA2129771C (en) 2006-03-21
JPH0782250A (ja) 1995-03-28

Similar Documents

Publication Publication Date Title
KR100360954B1 (ko) 페닐알칸올아민유도체,이의제조방법및이를함유하는신경변성질환억제또는예방용약제
RU2105758C1 (ru) Гидрированные азотсодержащие гетероциклические соединения, производные пиперидина, фармацевтическая композиция и способ подавления активности вещества р в организме
CA2227814C (en) Substituted benzylaminopiperidine compounds
FR2696178A1 (fr) Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant.
EP1682503A2 (fr) Derives de n-[phenyl(alkylpiperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
SK279168B6 (sk) Bicyklické 1-azacykloalkány, farmaceutické prostri
HUT67589A (en) Process for producing 5-(1-aminocycloxyl)-2(1h)-pyridinone derivatives and pharmaceutical compositions comprising them
IE912760A1 (en) Compounds
US4806547A (en) Isoquinoline derivatives, analgesic compounds thereof and method of treating pain
EP0674514A1 (en) Use of aryloxyalkyl substituted cyclic amines as calcium channel antagonists and new phenyloxyalkyl piperidin derivatives
US5332817A (en) 3-aminopiperidine derivatives and related nitrogen containing heterocycles
EP0030526B1 (en) New phenyl-azacycloalkanes, processes for preparation and pharmaceutical preparations for such compounds
US5231092A (en) Hexahydroazepine derivatives and pharmaceutical compositions containing them
JPH0670026B2 (ja) １，４−二置換ピペラジン誘導体、これを含む薬剤組成物およびその製造方法
CA1105026A (en) 4a-aryl-octahydro-1h-2-pyrindines
EP2358369A1 (en) Process for the preparation of substantially optically pure repaglinide and precursors thereof
EP0971929A1 (fr) DERIVES DE 2,3-DIHYDROFURO 3,2-$i(b)]PYRIDINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
AU610492B2 (en) 5-substituted octahydroindolizine analgesics compounds and 7-keto intermediates
NO170580B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive piperidinderivater
SK6412000A3 (en) Biphenyl derivatives as pharmaceuticals
JPS624250A (ja) ベンズ三置換−２−アミノテトラリン
EP2177221A1 (en) Process for the preparation of substantially optically pure Repaglinide and precursors thereof
JPS6140247A (ja) フエニルエチルアミノプロピオフエノン誘導体
EP2419431A1 (fr) Derives de n-[(7-aza-bicyclo[2.2.1]hept-1-yl)-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique
EP0062018A1 (en) Novel phenyl-piperidines

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20050930

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20061101

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20061101

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000